LurexBio is designed to give cold tumors a recognition signal the immune system already knows how to see, in place before downstream immunotherapies ever engage. Four components make that layer work: NeoTag provides the signal, Atraxis brings it to the tumor surface, AegisCore helps keep activity controlled, and StratIQ brings the system together.
Platform capabilities described on this page are design objectives grounded in published biology. No efficacy data exist.
Each component below is grounded in its own independently published area of biology or engineering. What is untested, and what our early-stage research is designed to test, is whether they function together as one programmable platform.
Many cold tumors don't give the immune system a clear enough signal to attack -- there's no obvious flag to rally around.
NeoTag™ is a synthetic immune flag designed to resemble something the immune system already knows is foreign. Instead of asking the immune system to learn an entirely new target, NeoTag is designed to use recognition the body may already have. No genetic alteration and no viral vector.
Even a well-designed signal is useless without a way to install it directly at the tumor surface, and without altering the tumor's own genome.
A delivery platform designed to carry and establish NeoTag™ directly at the tumor surface. No genetic alteration, no viral vector. This is our initial approach, designed to be adaptable rather than fixed.
An immune-activating platform that cannot be controlled is a liability, not a therapy. Where and when it acts matters as much as whether it works.
Programmable activation controls designed to restrict platform activity to the intended target, time window, and therapeutic context.
Four independently engineered components do not add up to a coordinated system on their own. Something has to decide when and how they act together.
The coordination architecture designed to integrate NeoTag™, Atraxis™, and AegisCore™ into a single controllable platform.
Each component builds on established science -- immunology, membrane biology, synthetic biology, and decision architecture all have decades of precedent behind them.
What's new is how LurexBio brings these capabilities together: combining four independently grounded mechanisms into a single coordinated, non-genetic platform, which is what our early-stage research is designed to test.*
Each component is protected separatelyLurexBio is pursuing a layered intellectual property strategy across the platform's components and their combination -- not relying on a single point of protection. That's a deliberate part of how we think about defensibility, not just design.
Established science, novel combination -- our early-stage research is designed to test each critical piece, and then whether they function together as one platform.